Pioneers in Immunoregulatory Drug Discovery and Development

We develop novel immunoregulatory therapeutics for patients with autoimmune diseases, starting with ulcerative colitis and Crohn’s disease.

Our Mission

We are a late-clinical-stage precision immunology biopharmaceutical company focused on the development of best-in-class biomarker-driven immunoregulatory therapeutics. Our lead clinical candidate, omilancor, is a Phase 3-ready, first-in-class, oral, gut-restricted LANCL2 agonist for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD).

Our management team has significant experience in development of immunoregulatory drugs and a proven track record of effectively accelerating drug candidates into and through late-stage clinical development. We are on a mission to develop safer and more effective therapeutics that address the unmet needs of patients with autoimmune diseases.

Press and Articles from NImmune

Press Release
NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral treatment with NIM-1324 is well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 induces a dose-proportional change in plasma exposure...

Read More

Press Release
NImmune Biopharma Announces Publication on the Safety, Efficacy and Novel LANCL2 Mechanism of Action of Omilancor in Inflammatory Bowel Diseases

NImmune Biopharma Announces Publication on the Safety, Efficacy and Novel LANCL2 Mechanism of Action of Omilancor in Inflammatory Bowel Diseases

This publication describes novel LANCL2-based immunoregulatory mechanisms that enhance regulatory T cells (Tregs) anti-inflammatory functions by amplifying IL-2 signaling and promote T cell metabolic reprogramming resulting in enhanced mitochondrial metabolism...

Read More

Press Release
NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

Once-a-day oral dosing with omilancor induced clinical remission in 30.4% of active Ulcerative Colitis (UC) patients versus 3.7% in the placebo group (Δ=26.7%, P = 0.01) Once-a-day oral dosing with omilancor in active Crohn’s disease (CD) patients shows promising...

Read More

NImmune Leadership Team

A highly experienced and talented team with deep knowledge of LANCL therapeutics and a proven track record of biotech industry success.

Product Candidates

NImmune’s clinical development pipeline includes best-in-class biomarker-driven immunoregulatory therapeutics for autoimmune diseases with multiple catalyst milestones. Lead clinical candidate omilancor, a Phase 3-ready immunoregulatory therapeutic targeting LANCL2, is an oral, once-daily, gut-restricted, first-in-class therapeutic for Ulcerative Colitis and Crohn’s disease with registration-directed pivotal clinical trials planned for 2023 with data readout in 12-18 months.

Learn more about the omilancor story, LANCL2 mechanism of action, and the market opportunity we seek to address.

Contact Us

If you would like to know more about our research, please fill out the form below.

Contact Us

Name(Required)